

Interstitial Lung Disease in Primary Immunodeficiency: Towards a Brighter Future

Hurst JR and Warnatz K on behalf of the ERS eGLILDnet Clinical Research Collaboration (see below)

Lung disease is a frequent clinical manifestation in people living with primary immunodeficiency diseases, the most prevalent of which are Common Variable Immunodeficiency Disorders (CVID). CVID is primarily characterised by antibody deficiency, but recent definitions and diagnostic criteria recognise a much more complex pattern of immunological defects [1]. CVID can be classified into two major clinical phenotypes. One group experiences infections as the only major clinical manifestation, whilst the other present a variety of lymphoproliferative, inflammatory and/or autoimmune complications. The most frequent consequences in the lung of CVID are acute infections, and secondary airway complications of infection such as bronchiectasis. However, up to 15% of patients with CVID develop an interstitial lung disease [2, 3]. Infections and bronchiectasis are primarily driven by antibody deficiency, but CVID associated interstitial lung disease (CVID-ILD) is best considered part of a systemic immunodysregulatory process [4] such that people with CVID-ILD often have splenomegaly, lymphadenopathy and autoimmune cytopenias [5-7]. With an EU population of 747 million, we estimate there are up to 30,000 people living with CVID in Europe, and thus 4,500 with CVID-ILD. Whilst people with ‘infection only’ CVID can now expect a near normal life expectancy [8], those with systemic immune dysregulation including CVID-ILD often have a much more complicated course. CVID-ILD increases morbidity and mortality in CVID [9], although the outcome is now recognised to be more variable than originally reported [10].

The terminology in use for ILD in CVID is complex and there is no consensus. The term Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD) is in common use but there need not be granuloma. We previously proposed the following working definition of GLILD: *“GLILD is a distinct clinico-radio-pathological ILD occurring in patients with CVID, associated with a lymphocytic infiltrate and/or granuloma in the lung, and in whom other conditions have been considered and where possible excluded”* [11]. Lung pathology and its radiological correlate in CVID-ILD/GLILD are heterogeneous including frequent ground-glass opacities due to lymphocytic interstitial pneumonitis, organizing pneumonia, and larger, often bronchocentric nodules - often in the context of background bronchiectasis [12, 13] (Figure). No pathogen has been identified and the mechanism is likely immune dysregulation. Histology is characterised by combined T- and B-lymphocytic infiltrates, partly creating tertiary lymphoid structures within the lung and associated with increased levels of the B-cell activating factor BAFF [14]. The frequent coincidence of lymphadenopathy raises the important differential diagnoses of sarcoid and lymphoma. Associated laboratory abnormalities include elevated soluble IL-2 receptor, β 2 microglobulin and neopterin, together with the hypogammaglobulinemia that is the hallmark of CVID and which facilitates differentiation from sarcoidosis in previously undiagnosed patient with CVID-ILD.

Managing patients with rare diseases is challenging in the absence of robust evidence. Many questions about the pathogenesis, diagnosis and management of GLILD remain. Is a lung biopsy necessary? What constitutes optimal treatment given that the available evidence, such as it is, remains based on case reports and small case series [15-18]? The relevance of B cells in the pathogenesis of CVID-ILD/GLILD is underlined by the reported effectiveness of rituximab [19]. New treatments in ILD such as nintedanib and pirfenidone have not been tested in CVID-ILD/GLILD, although fibrosis is not a prominent feature of CVID-ILD/GLILD.

To understand current management, we conducted a survey in the UK to assess diagnostic work up, and how clinicians were making treatment decisions including starting criteria, choice of drug, and endpoints such as symptoms, lung function and radiology [11]. The large (observational) European STILPAD (Study of interstitial lung disease in primary antibody deficiency) study will shortly report retrospective results, adding to the existing literature. Such evidence is urgently required to better treat people with this condition.

With considerable progress in understanding and treating other ILD, it becomes increasingly frustrating and unacceptable not to address the challenges in managing CVID-ILD/GLILD. To this end, we are pleased to announce the launch of a European Respiratory Society Clinical Research Collaborations (ERS CRC) to address CVID-ILD/GLILD, called eGLILDnet. As has been previously described, ERS CRCs are established to promote the exchange of research ideas among clinicians and scientists in Europe and more widely and to plan, conduct, evaluate and publish clinical and translational studies [20].


eGLILDnet will create a multi-professional network that is designed to establish a virtual multidisciplinary team (MDT) for case-based expert discussion in collaboration with ERN RITA, and a registry for cases (ERN RITA is the European Reference Network for immunodeficiency, autoinflammatory and autoimmune disease). We will go on to complete a research prioritisation exercise, ultimately advocating for and delivering necessary practice changing research in CVID-ILD/GLILD. Only by wide, transparent, multi-professional and trans-disciplinary collaboration across Europe can we strive to deliver a brighter future for those affected by CVID-ILD/GLILD. Like all CRCs, eGLILDnet is a collaboration of patients, clinicians, scientists and industry, and designed to support training through the involvement of early-career researchers.

How can you help? If you would like to join us, please contact the co-chairs. You can follow updates on Twitter (@eGLILDnet) or at our website <https://www.ersnet.org/research/e-glildnet---a-european-granulomatous-lymphocytic-interstitial-lung-disease-network>.

And practically? Always remember to measure serum immunoglobulins in people with SPUR (severe, persistent, unusual or recurrent) infections, bronchiectasis and interstitial lung disease, particularly sarcoidosis, to avoid missing primary immunodeficiency.

Figure:

Typical CT chest scan from a patient with CVID at the time of initial diagnosis with GLILD. The patient was asymptomatic but had impairment in gas transfer. The CT also demonstrated splenomegaly.



Collaborators (to have names visible as Authors on PubMed).

Tiago M Alfaro, Pneumology Unit, Centro Hospital e Universitário de Coimbra, Coimbra, Portugal and Centre of Pneumology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

Ulrich Baumann, Paediatric Pulmonology, Allergy and Neonatology, Hannover Medical School, Hanover, Germany, European Union

Anne Bergeron, Université de Paris, APHP Hôpital Saint Louis, UMR 1153 CRESS, F-75010, Paris, France

Siobhan O Burns, Institute of Immunity and Transplantation, University College London, London, UK, Department of Immunology, Royal Free London NHS Foundation Trust, London, UK

Alison Condliffe, Department of Infection, Immunity and Cardiovascular Diseases, University of Sheffield Medical School, Sheffield, UK

Andrew R Gennery, Translational and Clinical Research Institute, Newcastle University and Great North Children's Hospital, Newcastle upon Tyne

Filomeen Haerynck, Department of Pediatric Pulmonology and Immunology, Centre for Primary Immune deficiency Ghent, PID research lab, Ghent University Hospital, Belgium.

Joseph Jacob, UCL Respiratory, University College London and Centre for Medical Image Computing, University College London, London, UK

Stephen Jolles, Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.

Marion Malphettes, Department of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris, France. EA3518, Université Paris Diderot, Paris 7, Paris, France.

Véronique Meignin, Department of Pathology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris, France

Tomas Milota, Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, the Czech Republic

Antje Prasse, Department of Pulmonology, Hannover Medical School and DZL BREATH, Hannover, Germany and Fraunhofer ITEM, Hannover, Germany

Isabella Quinti, Department of Molecular Medicine, Sapienza University of Rome

Elisabetta Renzoni, Royal Brompton Hospital, London, UK

Daiana Stolz, Clinic for Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Petersgraben 4, 4031 - Basel, Switzerland

Annick A.J.M. van de Ven, Departments of Internal Medicine and Allergology, Rheumatology and Clinical Immunology, University Medical Center Groningen, the Netherlands

References

1. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. *J Allergy Clin Immunol Pract*. 2016;4(1):38–59. doi:10.1016/j.jaip.2015.07.025
2. Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. *Lancet Respir Med*. 2015;3(8):651–660. doi:10.1016/S2213-2600(15)00202-7
3. van de Ven AA, de Jong PA, Hoytema van Konijnenburg DP, et al. Airway and interstitial lung disease are distinct entities in paediatric common variable immunodeficiency. *Clin Exp Immunol*. 2011;165(2):235–242. doi:10.1111/j.1365-2249.2011.04425.x
4. Schussler E, Beasley MB, Maglione PJ. Lung Disease in Primary Antibody Deficiencies. *J Allergy Clin Immunol Pract*. 2016;4(6):1039–1052. doi:10.1016/j.jaip.2016.08.005
5. Hartono S, Motosue MS, Khan S, et al. Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency. *Ann Allergy Asthma Immunol*. 2017;118(5):614–620. doi:10.1016/j.anai.2017.01.004
6. Feuille EJ, Anooshiravani N, Sullivan KE, Fuleihan RL, Cunningham-Rundles C. Autoimmune Cytopenias and Associated Conditions in CVID: a Report From the USIDNET Registry. *J Clin Immunol*. 2018;38(1):28–34. doi:10.1007/s10875-017-0456-9
7. Mannina A, Chung JH, Swigris JJ, et al. Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease. *Ann Am Thorac Soc*. 2016;13(7):1042–1049. doi:10.1513/AnnalsATS.201511-728OC
8. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. *Blood*. 2012;119(7):1650–1657. doi:10.1182/blood-2011-09-377945
9. Bates CA, Ellison MC, Lynch DA, Cool CD, Brown KK, Routes JM. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. *J Allergy Clin Immunol*. 2004;114(2):415–421. doi:10.1016/j.jaci.2004.05.057
10. Maglione PJ, Overbey JR, Cunningham-Rundles C. Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings. *J Allergy Clin Immunol Pract*. 2015;3(6):941–950. doi:10.1016/j.jaip.2015.07.004
11. Hurst JR, Verma N, Lowe D, et al. British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. *J Allergy Clin Immunol Pract*. 2017;5(4):938–945. doi:10.1016/j.jaip.2017.01.021
12. Prasse A, Kayser G, Warnatz K. Common variable immunodeficiency-associated granulomatous and interstitial lung disease. *Curr Opin Pulm Med*. 2013;19(5):503–509. doi:10.1097/MCP.0b013e3283642c47
13. Patel S, Anzilotti C, Lucas M, Moore N, Chapel H. Interstitial lung disease in patients with common variable immunodeficiency disorders: several different pathologies?. *Clin Exp Immunol*. 2019;198(2):212–223. doi:10.1111/cei.13343

14. Maglione PJ, Gyimesi G, Cols M, et al. BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency. *JCI Insight*. 2019;4(5):e122728. Published 2019 Mar 7. doi:10.1172/jci.insight.122728
15. Chase NM, Verbsky JW, Hintermeyer MK, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). *J Clin Immunol*. 2013;33(1):30–39. doi:10.1007/s10875-012-9755-3
16. Cinetto F, Scarpa R, Pulvirenti F, Quinti I, Agostini C, Milito C. Appropriate lung management in patients with primary antibody deficiencies. *Expert Rev Respir Med*. 2019;13(9):823–838. doi:10.1080/17476348.2019.1641085
17. Deyà-Martínez A, Esteve-Solé A, Vélez-Tirado N, et al. Sirolimus as an alternative treatment in patients with granulomatous-lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells. *Pediatr Allergy Immunol*. 2018;29(4):425–432. doi:10.1111/pai.12890
18. Bucciol G, Petrone A, Putti MC. Efficacy of mycophenolate on lung disease and autoimmunity in children with immunodeficiency. *Pediatr Pulmonol*. 2017;52(10):E73–E76. doi:10.1002/ppul.23757
19. Pecoraro A, Crescenzi L, Galdiero MR, et al. Immunosuppressive therapy with rituximab in common variable immunodeficiency. *Clin Mol Allergy*. 2019;17:9. Published 2019 May 6. doi:10.1186/s12948-019-0113-3
20. Brightling C, Genton C, Bill W, et al. ERS Clinical Research Collaborations: underpinning research excellence. *Eur Respir J*. 2018;52(3):1801534. Published 2018 Sep 15. doi:10.1183/13993003.01534-2018